5 Star
.
.
.

Baumhefner said for many patients with breakthrough disease on standard IFNβ-1a, increasing the treatment dosage with twice-weekly therapy may be an acceptable alternative to switching treatments.

June Halper, MSN, MSCN, CMCS CEO, agreed, noting that "it makes a lot of sense for some patients to stay on a drug that has worked for them, and tweak the therapy if there is a breakthrough instead of automatically moving on to another drug," she told MedPage Today.

Baumhefner said a prospective, blinded, randomized trial comparing once-weekly and twice-weekly intramuscular IFNβ-1a may be warranted.

.

Payments processed through Visa's systems account for ?1 in ?3 of all ...
.

.
.
.
Features http://game-rapidshare.com/Gennett-brother-of-Throneberry-from-Ottmarsheim?Caldergra=256
.

.
.
.
.
Some men with prostate cancer could live longer thanks to immunotherapy
.
.
.

Scientists have discovered dunes on Pluto, and say they are likely to have been formed of methane ice grains released into its rarefied atmosphere.

Dawn mission: new orbit, new opportunities

May 31, 2018